Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.66 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648331 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5598310 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5429914 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL3073495 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL10535915 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL24073266 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| N-(Decanoyl)Hexamethyleneimine SCHEMBL6012122 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL10481691 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL5433045 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL3840069 | 1.00 | L3MBTL1 (0.96) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | MACRO CHEM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070190019-A1 | Compositions and methods for topical administration | MACROCHEM CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20050032900-A1 | Ibuprofen salt emulsifiers and cream formulations containing same | MACROCHEM CORPORATION | 2005-02-10 | — | — | US | disclosed |
| EP-1432405-A1 | IBUPROFEN SALT EMULSIFIERS AND CREAM FORMULATIONS CONTAINING SAME | MacroChem Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028702-A1 | IBUPROFEN SALT EMULSIFIERS AND CREAM FORMULATIONS CONTAINING SAME | MACROCHEM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| US-5204339-A | Administering alkylthioformylazacycloalkane with therapeutic agent | WHITBY RESEARCH, INC. (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0258385-A4 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES. | NELSON RES & DEV COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0268219-A1 | Penetration enhancers for transdermal delivery of systemic agents | Whitby Research Incorporated (US) | 1988-05-25 | — | — | EP | disclosed |
| EP-0258385-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES | Whitby Research Incorporated (US) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987004593-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1987-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | CYP8B1, NR1H3, NR1H2 | L3MBTL1 4884/4885MEN1 4663/4885KMT2A 4753/4885 |
| US-20050032900-A1 | Ibuprofen salt emulsifiers and cream formulations containing same | ALOX12, NAPEPLD, ACMSD | L3MBTL1 4759/4885MEN1 4846/4885KMT2A 3244/4885 |
| US-20070190019-A1 | Compositions and methods for topical administration | DSG1, CUTA, KRT18 | L3MBTL1 4741/4885MEN1 2717/4885KMT2A 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.